Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

K. Owonikoko, Taofeek; E. Dahlberg, Suzanne; Sica, Gabriel; I. Wagner, Lynne; L. Wade, James; Srkalović, Gordan; W. Lash, Bradley; W. Leach, Joseph; B. Leal, Ticiana; Aggarwal, Charu; S. Ramalingam, Suresh

doi:10.1200/jco.18.00264

Public

Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study

Published in Journal of Clinical Oncology • Dec 6, 2018

Authors:

Taofeek K. Owonikoko

Suzanne E. Dahlberg

Gabriel Sica

Abstract

PURPOSE: Veliparib, a poly (ADP ribose) polymerase inhibitor, potentiated standard chemotherapy against small-cell lung cancer (SCLC) in preclinical studies. We evaluated the combination of veliparib with cisplatin and etoposide (CE; CE+V) doublet in untreated, extensive-stage SCLC (ES-SCLC). MATERI...

Subject

Medicine

Veliparib

Hazard ratio

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!